Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Multiple Sclerosis Functional Composite

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    40 result(s) found for: Multiple Sclerosis Functional Composite. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2009-011516-37 Sponsor Protocol Number: 14022009 Start Date*: 2009-05-29
    Sponsor Name:Danish Multiple Sclerosis Research Centre
    Full Title: Double blind, placebo-controlled study to assess the effects of Erythropoietin on clinical disability and brain pathology as shown by magnetic resonance imaging in patients with progressive multipl...
    Medical condition: Multiple Sclerosis, with primary and secondary progressive courses.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028245 Multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005262-35 Sponsor Protocol Number: 16401 Start Date*: 2013-07-08
    Sponsor Name:Bayer HealthCare AG
    Full Title: BENEFIT 11 a long-term, follow-up study (16401) of the BENEFIT (304747), BENEFIT Follow-up (305207) Studies and BENEFIT Extension (311129) Study to further evaluate the progress of patients with fi...
    Medical condition: Clinically isolated syndrome (CIS) and multiple sclerosis (MS)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    14.1 10029205 - Nervous system disorders 10071068 Clinically isolated syndrome PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) SE (Completed) PT (Completed) HU (Completed) CZ (Completed) NO (Completed) AT (Completed) FI (Completed) DK (Completed) GB (Completed) ES (Completed) IT (Completed) SI (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-001176-31 Sponsor Protocol Number: 19215 Start Date*: 2017-09-22
    Sponsor Name:Bayer AG,
    Full Title: BENEFIT 15 long-term follow-up study of the BENEFIT and BENEFIT follow-up studies
    Medical condition: Clinically-isolated syndrome (CIS) and multiple sclerosis (MS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    20.0 10029205 - Nervous system disorders 10071068 Clinically isolated syndrome PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) ES (Completed) SE (Completed) GB (Completed) AT (Completed) CZ (Completed) FI (Completed) DK (Completed) BE (Completed) FR (Completed) PT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-007015-32 Sponsor Protocol Number: CENA713DDE18 Start Date*: Information not available in EudraCT
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A 16-week, multicenter, double-blind, randomized, placebo-controlled, parallel group study to evaluate the efficacy of rivastigmine (Exelon® patch 10 cm2) on cognitive deficits in patients with mul...
    Medical condition: cognitive impairment in Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028245 Multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-000700-29 Sponsor Protocol Number: MD1003CT2016-01MS-SPI2 Start Date*: 2017-02-01
    Sponsor Name:MEDDAY PHARMACEUTICALS SA
    Full Title: Effect of MD1003 in progressive multiple sclerosis: a randomized double-blind placebo-controlled study.
    Medical condition: Multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SE (Completed) DE (Prematurely Ended) ES (Prematurely Ended) HU (Completed) BE (Completed) PL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-005125-11 Sponsor Protocol Number: RCT-EPO-001 Start Date*: 2008-12-19
    Sponsor Name:Walton Centre for Neurology and Neurosurgery
    Full Title: A pilot single-centre randomised controlled trial of recombinant human erythropoietin versus placebo in primary progressive multiple sclerosis.
    Medical condition: Primary progressive multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063401 Primary progressive multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-000253-92 Sponsor Protocol Number: EHP-101-MS02 Start Date*: 2022-10-14
    Sponsor Name:Emerald Health Pharmaceuticals Inc.
    Full Title: A Phase IIa, Open-label, Multicentre Dose-Finding Trial in Patients with Relapsing Forms of Multiple Sclerosis (RMS) to Evaluate the Safety, Tolerability and Preliminary Efficacy of EHP-101
    Medical condition: Relapsing Forms of Multiple Sclerosis (RMS)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029205 - Nervous system disorders 10080700 Relapsing multiple sclerosis PT
    21.1 10029205 - Nervous system disorders 10063400 Secondary progressive multiple sclerosis PT
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-004847-61 Sponsor Protocol Number: 008717QM Start Date*: 2013-01-16
    Sponsor Name:Queen Mary University of London
    Full Title: A phase II baseline versus treatment study to determine the efficacy of raltegravir (ISENTRESS) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhan...
    Medical condition: Relapsing Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-004579-22 Sponsor Protocol Number: GAM-25 Start Date*: 2008-10-14
    Sponsor Name:Octapharma AG
    Full Title: A prospective, multicentre, open label, exploratory study to investigate the ability of the Heidelberg Assay Panel and the B-Cell /Antibody response panel to predict the clinical effect of Octagam ...
    Medical condition: Subjects with RR Multiple Sclerosis in whom intravenous immunoglobulin (IVIG) treatment is clinically indicated because first-line treatments are contraindicated or not tolerated.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-003176-39 Sponsor Protocol Number: 205MS303 Start Date*: 2013-05-31
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Multicenter, Open-Label, Extension Study to Evaluate the Long Term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), Monotherapy in Subjects With Multiple Sclerosis Who Hav...
    Medical condition: Relapsing-remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) IT (Prematurely Ended) CZ (Completed) HU (Completed) PL (Completed) SE (Completed) ES (Completed) IE (Prematurely Ended) GB (Completed) FI (Prematurely Ended) GR (Completed) FR (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2012-002639-27 Sponsor Protocol Number: MT-1303-E05 Start Date*: 2013-03-11
    Sponsor Name:Mitsubishi Tanabe Pharma Corporation (MTPC)
    Full Title: A phase II, multicentre study to evaluate the long-term safety and efficacy of MT-1303 in subjects with relapsing-remitting multiple sclerosis who have completed the MT-1303-E04 study
    Medical condition: Relapsing-remitting multiple sclerosis (RRMS)
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) ES (Completed) FI (Completed) BE (Completed) LT (Completed) CZ (Completed) PL (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-015319-41 Sponsor Protocol Number: TSO-MS Start Date*: 2011-11-03
    Sponsor Name:Charite Universitätsmedizin Berlin
    Full Title: Trichuris suis Oozyten (TSO®) in remittent-recurrent Multiple Sclerosis (MS) and Clinically Isolated Syndrom (CIS)
    Medical condition: remittent-recurrent Multiple Sclerosis (MS) and Clinically Isolated Syndrom (CIS)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-003696-12 Sponsor Protocol Number: 109MS301 Start Date*: 2007-03-02
    Sponsor Name:Biogen Idec Ltd.
    Full Title: A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose-Comparison Study to Determine the Efficacy and Safety of BG00012 in Subjects with Relapsing-Remitting Multiple Sclerosis
    Medical condition: Relapsing-Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10063399 Relapsing-remitting multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) SK (Completed) DE (Completed) CZ (Completed) AT (Completed) SE (Prematurely Ended) NL (Completed) GR (Completed) IT (Completed) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-001161-14 Sponsor Protocol Number: CAMMS 323 Start Date*: 2007-08-24
    Sponsor Name:Genzyme Corporation
    Full Title: A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in treatment Naïve Patients with Rela...
    Medical condition: Relapsing Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063399 Relapsing-remitting multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) CZ (Completed) SE (Completed) FR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-002470-31 Sponsor Protocol Number: MT-1303-E04 Start Date*: 2012-10-29
    Sponsor Name:Mitsubishi Tanabe Pharma Corporation (MTPC)
    Full Title: A phase II, multicentre, randomised, double-blind, parallel group, placebo-controlled, dose-finding study to evaluate the safety and efficacy of three different oral doses of MT-1303 administered f...
    Medical condition: Relapsing-Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) LT (Completed) CZ (Completed) HU (Completed) FI (Completed) BE (Completed) IT (Completed) PL (Completed) BG (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-000894-26 Sponsor Protocol Number: BN42083 Start Date*: 2020-10-12
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE IIIB MULTICENTER, RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACOKINETICS OF A HIGHER DOSE OF OCRELIZUMAB IN ADULTS WITH PRIMARY PROGRESSIVE MULTIPL...
    Medical condition: Primary Progressive Multiple Sclerosis (MS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063401 Primary progressive multiple sclerosis PT
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    20.1 10029205 - Nervous system disorders 10039720 Sclerosis multiple LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: PT (Trial now transitioned) GB (GB - no longer in EU/EEA) HU (Trial now transitioned) FR (Trial now transitioned) DE (Trial now transitioned) DK (Trial now transitioned) BE (Trial now transitioned) GR (Trial now transitioned) IT (Trial now transitioned) BG (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-001166-29 Sponsor Protocol Number: inims-009 Start Date*: 2020-03-18
    Sponsor Name:University Medical Centre Hamburg-Eppendorf
    Full Title: A randomised controlled trial to compare ocrelizumab or alemtuzumab with autologous hematopoietic stem cell transplantation (aHSCT) in high inflammatory multiple sclerosis (COAST)
    Medical condition: relapsing-remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-002547-17 Sponsor Protocol Number: VU-49636 Start Date*: 2014-12-18
    Sponsor Name:VU University Medical Center
    Full Title: Grey matter microglial imaging with [18F]DPA-714 in progressive MS patients
    Medical condition: Progressive multiple sclerosis, both primary and secondary progressive
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029205 - Nervous system disorders 10063401 Primary progressive multiple sclerosis PT
    17.1 10029205 - Nervous system disorders 10063400 Secondary progressive multiple sclerosis PT
    17.1 10029205 - Nervous system disorders 10053395 Progressive multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-020315-36 Sponsor Protocol Number: WA21093 Start Date*: 2011-10-18
    Sponsor Name:F.Hoffmann-La Roche
    Full Title: A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sc...
    Medical condition: Relapsing Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SK (Completed) BE (Completed) SE (Completed) DE (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) BG (Completed) FR (Completed) IE (Completed) IT (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2009-012500-11 Sponsor Protocol Number: 205MS301 Start Date*: 2010-04-12
    Sponsor Name:Biogen Idec Ltd
    Full Title: Multicenter, Double-blind, Randomized, Parallel-group, Monotherapy, Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) versus Avonex® (Interferon β...
    Medical condition: Relapsing-remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IE (Completed) FR (Completed) DE (Completed) CZ (Completed) HU (Completed) FI (Completed) SE (Completed) ES (Completed) GB (Completed) GR (Completed) IT (Completed) DK (Completed) SI (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jun 10 23:02:35 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA